Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6


Tumor Suppressor Activity of Klotho in Breast Cancer Is Revealed by Structure-Function Analysis.

Ligumsky H, Rubinek T, Merenbakh-Lamin K, Yeheskel A, Sertchook R, Shahmoon S, Aviel-Ronen S, Wolf I.

Mol Cancer Res. 2015 Oct;13(10):1398-407. doi: 10.1158/1541-7786.MCR-15-0141. Epub 2015 Jun 25.


Cyclophosphamide triggers follicle activation and "burnout"; AS101 prevents follicle loss and preserves fertility.

Kalich-Philosoph L, Roness H, Carmely A, Fishel-Bartal M, Ligumsky H, Paglin S, Wolf I, Kanety H, Sredni B, Meirow D.

Sci Transl Med. 2013 May 15;5(185):185ra62. doi: 10.1126/scitranslmed.3005402.


The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.

Ligumsky H, Wolf I, Israeli S, Haimsohn M, Ferber S, Karasik A, Kaufman B, Rubinek T.

Breast Cancer Res Treat. 2012 Apr;132(2):449-61. doi: 10.1007/s10549-011-1585-0. Epub 2011 Jun 3.


KL1 internal repeat mediates klotho tumor suppressor activities and inhibits bFGF and IGF-I signaling in pancreatic cancer.

Abramovitz L, Rubinek T, Ligumsky H, Bose S, Barshack I, Avivi C, Kaufman B, Wolf I.

Clin Cancer Res. 2011 Jul 1;17(13):4254-66. doi: 10.1158/1078-0432.CCR-10-2749. Epub 2011 May 13.


Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer.

Wolf I, Levanon-Cohen S, Bose S, Ligumsky H, Sredni B, Kanety H, Kuro-o M, Karlan B, Kaufman B, Koeffler HP, Rubinek T.

Oncogene. 2008 Nov 27;27(56):7094-105. doi: 10.1038/onc.2008.292. Epub 2008 Sep 1.


Butyrylcholinesterase attenuates amyloid fibril formation in vitro.

Diamant S, Podoly E, Friedler A, Ligumsky H, Livnah O, Soreq H.

Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8628-33. Epub 2006 May 26.

Supplemental Content

Loading ...
Support Center